Evidence map›Paper›PMID 34585225›Full record

ArticleThe journal of prevention of Alzheimer's disease2021

A Japanese Multicenter Study on PET and Other Biomarkers for Subjects with Potential Preclinical and Prodromal Alzheimer's Disease.

M Senda, K Ishii, K Ito, T Ikeuchi, H Matsuda, T Iwatsubo, A Iwata, R Ihara, K Suzuki, K Kasuga and 17 more

Open access · diamondAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in The journal of prevention of Alzheimer's disease, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.9field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors at 18 institutions in 1 country.

M SendaMichio Senda, Division of Molecular Imaging Research Kobe City Medical Center General Hospital (KCGH), 2-1-1 Minatojima-Minamimachi, Chuo-ku, Kobe 650-0047 Japan, E-mail: michio_senda@kcho.jp, Phone: 81-78-304-5212, Fax: 81-78-304-5201.
K Ishii
K Ito
T Ikeuchi
H Matsuda
T Iwatsubo
A Iwata
R Ihara
K Suzuki
K Kasuga
Y Ikari
Y Niimi
H Arai
A Tamaoka
Y Arahata
Y Itoh
H Tachibana
Y Ichimiya
S Washizuka
T Odawara
K Ishii
K Ono
T Yokota
A Nakanishi
E Matsubara
H Mori
H Shimada
The University of Tokyo · JPOsaka City University · JPKindai University · JPNational Center for Geriatrics and Gerontology · JPNiigata University · JPKobe City Medical Center General Hospital · JPKobe University · JPKoujin Hospital · JPNational Center of Neurology and Psychiatry · JPOita University · JPOsaka University · JPShinshu University · JPShowa University Hospital · JPTohoku University · JPTokyo Medical and Dental University · JPTokyo Metropolitan Geriatric Hospital · JPUniversity of Tsukuba · JPYokohama City University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPET (positron emission tomography) and CSF (cerebrospinal fluid) provide the "ATN" (Amyloid, Tau, Neurodegeneration) classification and play an essential role in early and differential diagnosis of Alzheimer's disease (AD).

objectiveBiomarkers were evaluated in a Japanese multicenter study on cognitively unimpaired subjects (CU) and early (E) and late (L) mild cognitive impairment (MCI) patients. MEASUREMENTS: A total of 38 (26 CU, 7 EMCI, 5 LMCI) subjects with the age of 65-84 were enrolled. Amyloid-PET and FDG-PET as well as structural MRI were acquired on all of them, with an additional tau-PET with 18F-flortaucipir on 15 and CSF measurement of Aβ1-42, P-tau, and T-tau on 18 subjects. Positivity of amyloid and tau was determined based on the positive result of either PET or CSF.

resultsThe amyloid positivity was 13/38, with discordance between PET and CSF in 6/18. Cortical tau deposition quantified with PET was significantly correlated with CSF P-tau, in spite of discordance in the binary positivity between visual PET interpretation and CSF P-tau in 5/8 (PET-/CSF+). Tau was positive in 7/9 amyloid positive and 8/16 amyloid negative subjects who underwent tau measurement, respectively. Overall, a large number of subjects presented quantitative measures and/or visual read that are close to the borderline of binary positivity, which caused, at least partly, the discordance between PET and CSF in amyloid and/or tau. Nine subjects presented either tau or FDG-PET positive while amyloid was negative, suggesting the possibility of non-AD disorders.

conclusionPositivity rate of amyloid and tau, together with their relationship, was consistent with previous reports. Multicenter study on subjects with very mild or no cognitive impairment may need refining the positivity criteria and cutoff level as well as strict quality control of the measurements.

Indexed as

Alzheimer DiseasePositron-Emission TomographyProdromal SymptomsAgedAged, 80 and overAmyloid beta-PeptidesBiomarkersCarbolinesCognitive DysfunctionHumansJapanMagnetic Resonance Imagingtau Proteins7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indoleAmyloid beta-PeptidesBiomarkersCarbolinestau ProteinsAlzheimer’s diseaseamyloidCSF biomarkerPETtau

Identifiers

PMID34585225
PMCPMC12280799
OpenAlexW3173455631

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.